Funding for this research was provided by:
Received: 3 June 2022
Accepted: 15 August 2022
First Online: 26 August 2022
: All participants gave written informed consent to participate in the study. Ethical approval was given by the regional ethics committee at Lund University, Sweden.
: Not applicable.
: OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens.